EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions Sylvie Marleau * , 1 , Diala Harb * , 1 , Kim Bujold * , 1 , Roberta Avallone * , Khadija Iken * , Yanfei Wang * , Annie Demers * , Martin G. Sirois † , Maria Febbraio ‡ , Roy L. Silverstein ‡ , André Tremblay § and Huy Ong * ,2 * Faculty of Pharmacy and Department of Pharmacology, Faculty of Medicine, Université de Montréal, Québec, Canada; † Montreal Heart Institute, Montréal, Québec, Canada; ‡ Department of Cell Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA; and § Ste-Justine Hospital Research Center, Québec, Canada 2 Correspondence: Faculty of Pharmacy, Université de Montréal, Pavillon Jean-Coutu, P.O. Box 6128, Station Centre-Ville, Montréal, Québec, Canada, H3C 3J7. E-mail: huy.ong@umontreal.ca <h3>SPECIFIC AIMS</h3> The original aim of the present study was to assess whether EP 80317, a novel CD36 ligand, may attenuate atherosclerotic disease progression in apoE-deficient (apoE –/– ) mice fed a high fat, high cholesterol (HFHC) diet, using apoE/CD36 double-deficient (apoE –/– /CD36 –/– ) mice as negative controls. We observed a striking, CD36-dependent anti-atherosclerotic effect of
/lp/fed-of-american-socs-for-experimental-biology/ep-80317-a-ligand-of-the-cd36-scavenger-receptor-protects-GSQKp0OE03